Lobeglitazone Sulfate/Metformin Hydrochloride

洛贝格列酮硫酸盐/盐酸二甲双胍

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLobeglitazone Sulfate/Metformin Hydrochloride

Drug Alias Name洛贝格列酮+二甲双胍Lobeglitazone+metformin洛贝格列酮/二甲双胍metformin+Lobeglitazone洛贝格列酮硫酸盐+盐酸二甲双胍 +[12]

ClassificationSmall molecules

Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsPeroxisome proliferator-activated receptor γ agonistsPeroxisome proliferator-activated receptor α agonists

TargetsProtein kinase AMP-activated non-catalytic subunit beta 1Peroxisome proliferator-activated receptor γPeroxisome proliferator-activated receptor α

Therapy Area/IndicationsDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Metformin Hydrochloride Lobeglitazone Sulfate

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesChong Kun Dang Pharmaceutical Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesChong Kun Dang Pharmaceutical Corp

Active IndicationsN/A

Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A